We are live on ! Find out more
SPRY icon

ARS Pharmaceuticals
SPRY

74 hedge funds and large institutions have $287M invested in ARS Pharmaceuticals in 2021 Q3 according to their latest regulatory filings, with 19 funds opening new positions, 36 increasing their positions, 12 reducing their positions, and 20 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more repeat investments, than reductions

Existing positions increased: 36 | Existing positions reduced: 12

2.29% more ownership

Funds ownership: 80.18% → 82.46% (+2.3%)

5% less first-time investments, than exits

New positions opened: 19 | Existing positions closed: 20

3% less funds holding

Funds holding: 76 → 74 (-2)

67% less capital invested

Capital invested by funds: $864M → $287M (-$577M)

100% less funds holding in top 10

Funds holding in top 10: 2 → 0 (-2)

100% less call options, than puts

Call options by funds: $0 | Put options by funds: $136K

Holders
74
Holders Change
-2
Holders Change %
-2.63%
% of All Funds
1.3%
Holding in Top 10
–
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-100%
% of All Funds
–
New
19
Increased
36
Reduced
12
Closed
20
Calls
–
Puts
$136K
Net Calls
-$136K
Net Calls Change
-$136K

Top Buyers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
+$23.3M
2
WA
Wasatch Advisors
Utah
+$19.4M
3
Vanguard Group
Vanguard Group
Pennsylvania
+$16.6M
4
Morgan Stanley
Morgan Stanley
New York
+$15.4M
5
BlackRock
BlackRock
New York
+$8.59M

Top Sellers

Rank Fund Capital Flow
1
EC
EcoR1 Capital
California
-$35.3M
2
Ameriprise
Ameriprise
Minnesota
-$13.8M
3
EAM
Eventide Asset Management
Massachusetts
-$11.5M
4
Fidelity Investments
Fidelity Investments
Massachusetts
-$9.85M
5
CAM
Cormorant Asset Management
Massachusetts
-$7.39M
Name Holding Trade Value Shares
Change 		Change in
Stake
Renaissance Technologies
26
Renaissance Technologies
New York
$1.16M +$2.88M +116,600 New
CC
27
Commodore Capital
New York
$969K – – –
N
28
Nuveen
North Carolina
$759K +$494K +20,042 +36%
Citadel Advisors
29
Citadel Advisors
Florida
$743K +$983K +39,844 +115%
CSS
30
Cubist Systematic Strategies
Connecticut
$569K +$1.41M +56,981 +78,056%
Bank of New York Mellon
31
Bank of New York Mellon
New York
$566K +$422K +17,124 +43%
Goldman Sachs
32
Goldman Sachs
New York
$543K +$1.34M +54,349 New
JP Morgan Chase
33
JP Morgan Chase
New York
$495K +$1M +40,555 +446%
TI
34
Trexquant Investment
Connecticut
$451K +$1.12M +45,216 New
Ohio Public Employees Retirement System (OPERS)
35
Ohio Public Employees Retirement System (OPERS)
Ohio
$438K +$774K +31,382 +251%
Two Sigma Advisers
36
Two Sigma Advisers
New York
$375K +$927K +37,600 New
JF
37
Jump Financial
Illinois
$324K +$801K +32,500 New
HF
38
HRT Financial
New York
$259K +$642K +26,034 New
Swiss National Bank
39
Swiss National Bank
Switzerland
$231K – – –
Man Group
40
Man Group
United Kingdom
$231K +$238K +9,670 +72%
HS
41
HighVista Strategies
Massachusetts
$224K -$85.6K -3,472 -13%
RhumbLine Advisers
42
RhumbLine Advisers
Massachusetts
$200K +$82.2K +3,333 +20%
California State Teachers Retirement System (CalSTRS)
43
California State Teachers Retirement System (CalSTRS)
California
$196K +$52.6K +2,134 +12%
Walleye Trading
44
Walleye Trading
New York
$189K +$467K +18,956 New
HWM
45
Hohimer Wealth Management
Washington
$170K +$421K +17,077 New
Wells Fargo
46
Wells Fargo
California
$169K +$403K +16,323 +2,776%
OQS
47
Occudo Quantitative Strategies
Florida
$167K +$413K +16,765 New
State of Wisconsin Investment Board
48
State of Wisconsin Investment Board
Wisconsin
$165K +$247K +10,012 +154%
Squarepoint
49
Squarepoint
New York
$156K +$160K +6,492 +71%
PP
50
PDT Partners
New York
$156K +$385K +15,592 New
1
2
3 4

SPRY Hedge Fund Activity: Q3 2021 in Review

74 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in ARS Pharmaceuticals (SPRY) for Q3 2021, worth a combined $287M — down 67% from $864M a quarter earlier.

Sellers outnumbered buyers: 20 funds closed out of SPRY and 19 opened new positions — a net loss of 1 holder — while 12 trimmed existing stakes and 36 added.

The largest buyer was Millennium Management, adding an estimated $23.3M. The largest seller was EcoR1 Capital, cutting an estimated $35.3M.

  • 74 institutional investors held ARS Pharmaceuticals (SPRY) as of Q3 2021, down from 76 in Q2 2021.
  • Funds reported $287M of ARS Pharmaceuticals stock for Q3 2021, down 67% quarter-over-quarter.
  • 19 funds opened new ARS Pharmaceuticals positions in Q3 2021 and 20 closed out, a net change of -1 holder.
  • The largest ARS Pharmaceuticals buyer in Q3 2021 was Millennium Management, an estimated $23.3M added.
  • The largest ARS Pharmaceuticals seller in Q3 2021 was EcoR1 Capital, an estimated $35.3M sold.

Based on aggregated 13F filings for Q3 2021.